OR WAIT null SECS
The IQVIA Institute for Human Data Science released its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications. The report found that 15 new active substance (NAS) oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S. in 2018-which is a record. Those 2018 debuts bring the total number of new oncology therapeutics launched since 2013 to 57 covering 89 approved indications for 23 different tumor types.
In addition to detailing the influx of new oncology drugs within the R&D pipeline and marketplace, the Institute report explores health system barriers hindering the realization of the benefits of those therapies and drug candidates. The report further notes that despite extensive pipeline activity, oncology remains the most challenging area for research and development, facing significant risk of failure and long, costly development.